Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 5/2024

THE EFFECT OF SACUBITRIL/VALSARTAN COMBINED WITH METOPROLOL SUCCINATE SUSTAINED-RELEASE TABLET ON CARDIAC FUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE

XUEMEI LIU1, LINYAN TAN2, SHUBO YANG3, MINGHUA TANG1, HONG TAN1, FEI YANG4*

1 Cardiac function Room, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China
2 Department of Pharmacy, Tropical Agricultural Technology College, Hainan Vocational University, Haikou, 570216, China
3 Department of Cardiothoracic Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China
4 Department of Cardiology, Sanya Central Hospital (Hainan Third People’s Hospital), Sanya, 572029, China

Download Full Article PDF

Coronary artery disease (CAD) with heart failure (HF) is a common clinical condition. This study aimed to assess the effects of sacubitril/valsartan combined with metoprolol succinate extended-release tablets on cardiac function (CF) in patients with CAD and HF. A retrospective analysis of patients admitted between January 2018 and December 2020 was conducted. Patients were divided into two groups: an observation (Obs) group treated with sacubitril/valsartan and metoprolol succinate, and a control (Ctrl) group treated with metoprolol succinate alone. ECG parameters, vascular endothelial function (VEF), CF indicators, oxidative stress markers and clinical efficacy (CE) were compared. The Obs group showed significant improvements in left ventricular ejection fraction (LVEF), reduced left ventricular end-diastolic diameter (LVEDD) and lower levels of angiotensin II, sVCAM-1 and sICAM-1. Plasma nitric oxide (NO) levels increased, and cardiac biomarkers like NT-proBNP and cardiac troponin I (cTnI) decreased in the Obs group. The 6-minute walk test (6MWT) and oxidative stress markers (SOD, GPx) also improved. Overall, the Obs group had better CF, VEF and CE, with no significant difference in adverse events between the two groups. Sacubitril/valsartan combined with metoprolol shows potential benefits in managing CAD and HF.